Diagnosis of Alzheimer's disease patients with rapid cognitive decline in clinical practice: interest of the Deco questionnaire

J Nutr Health Aging. 2011 May;15(5):361-6. doi: 10.1007/s12603-011-0047-z.

Abstract

Background: Patients with Alzheimer's disease (AD) who deteriorate rapidly are likely to have a poorer prognosis. There is a clear need for a clinical assessment tool to detect such a decline in newly diagnosed patients.

Objective: To identify the predictive factors of rapid cognitive decline (RCD) in a cohort of patients with mild to moderate AD ; and to validate a self-questionnaire for caregivers as a diagnostic tool for rapid decline.

Design and analysis: An open-label, observational, 12-month, multicenter, French study. Physicians were asked to record data of three eligible rivastigmine naïve (or on rivastigmine for < 1 year) AD patients. Risk factors of RCD and the detection power of the Détérioration Cognitive Observée scale (Deco), a 19 item self-questionnaire for caregivers, were assessed at endpoint using regression analyses.

Results: Out of the 361 patients enrolled in the study, 91 (25.2%) were excluded due to loss of follow-up. Among subjects using cholinesterase inhibitors or memantine, 161 (59.6%) experienced a stabilization (29.2%) or an improvement (30.4%) in global functioning as measured by the CGI-C. Sixty of the remaining 204 patients retained for analysis (29.6%, CI 95% [23.4; 35.8]) lost three or more points on the MMSE score between the inclusion and one of the follow-up visit. In the multivariate logistic regression analysis, institutionalization, higher level of education and the loss of 3 points or more on the MMSE were found to be significant predictors of a rapid cognitive loss in this population. The threshold which maximizes the predictive values of the Deco score as a diagnostic tool of rapid cognitive decline was significantly different according to the age of the patient (below or over 75 years old). A score below 16 for patients < 75 years old and below 14 for patients ≥ 75 years old consistently predicted a RCD within the next year.

Conclusion: The Deco test appears to be a simple tool to alert the physician to the possibility of an aggressive course of the disease which warrants particular management.

Publication types

  • Multicenter Study
  • Validation Study

MeSH terms

  • Age Factors
  • Aged
  • Aged, 80 and over
  • Alzheimer Disease / complications
  • Alzheimer Disease / diagnosis*
  • Alzheimer Disease / drug therapy
  • Cholinesterase Inhibitors / therapeutic use
  • Cognition Disorders / diagnosis*
  • Cognition Disorders / etiology
  • Cohort Studies
  • Disease Progression
  • Educational Status
  • Female
  • Geriatric Assessment / methods*
  • Humans
  • Institutionalization
  • Logistic Models
  • Male
  • Memantine / therapeutic use
  • Middle Aged
  • Observation
  • Phenylcarbamates / therapeutic use
  • Qualitative Research
  • Risk Factors
  • Rivastigmine
  • Surveys and Questionnaires* / standards

Substances

  • Cholinesterase Inhibitors
  • Phenylcarbamates
  • Rivastigmine
  • Memantine